KOSPIHolding Companies008930

Hanmi Science

₩52,600▼ 3.31%2026-11-18 close
Market Cap
₩3.6T
Turnover
₩4.9B
Volume
90K
Shares out.
68.4M
PER
26.0×
PBR
3.3×
EPS
₩1,981
Dividend Yield
0.58%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩300 per share · Prices as of the 2026-11-18 close

01

Report overview

Hanmi Science: Earnings Recovery Amid Quarterly Swings

Hanmi Science's operating profit rose 40.3% in 2025 as earnings recovered, but third-quarter 2026 operating profit fell 51.3% year on year, leaving quarterly results volatile.

  1. 1

    Revenue rose for three consecutive years from 2023 through 2025, reaching KRW 1.36 trillion in 2025.

  2. 2

    Operating profit in 2025 was KRW 138.7 billion, with an operating margin of 10.2%, the largest year in the 2022–2025 period.

  3. 3

    Third-quarter 2026 operating profit was KRW 19.2 billion, down 51.3% year on year, reflecting a high base from a technology-export payment booked a year earlier at a subsidiary.

  4. 4

    The earnings structure combines low-margin pharmaceutical distribution revenue with reliance on equity-method income from subsidiaries and royalty income.

  5. 5

    Equity attributable to controlling shareholders stood at KRW 961.9 billion at end-2025, and net profit attributable to controlling shareholders for the last four quarters totaled KRW 134.2 billion.

02

Business structure

Hanmi Science is a holding company that also runs its own pharmaceutical distribution and healthcare businesses, a structure that dates to its 2022 merger with Hanmi Healthcare. Its equity stakes are 41.4% in Hanmi Pharm, 39.2% in JVM, and 100% in Online Pharm, the pharmaceutical distribution unit.

Most revenue comes from distribution; the distribution unit reported KRW 1.14 trillion in 2025 revenue in press coverage, a figure that is not a DART-filed amount.

Distribution carries thin margins, so real profit depends largely on equity-method income from subsidiaries and royalty income from patents, trademarks and technology exports. The healthcare business generated KRW 151.9 billion in 2025 revenue, up 19.6% year on year, according to press reports.

The cosmetics brand PRO-CALM reached KRW 12.1 billion in 2025 revenue, up 75%. In medical devices, the company holds global exclusive sales rights to three surgical hemostats developed by Terasion Biomedical: Oozfix, Tableau wax and ActiClot.

Its CAREMI care-food brand reportedly secured 440 pharmacy distribution points. Intra-group transactions are a notable structural feature, with returns tied closely to the performance of Hanmi Pharm and other affiliates.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩342.5B₩39.3B11.5%
2025Q4₩344B₩37.7B11.0%
2026Q1₩353.7B₩33.6B9.5%
2026Q2₩367.9B₩59.1B16.1%
2026Q3₩362.9B₩19.2B5.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩1T₩67.6B₩69.2B6.5%9.5%53.1%
2023₩1.2T₩124.5B₩115.1B10.0%14.6%55.7%
2024₩1.3T₩98.9B₩59.4B7.7%7.1%60.9%
2025₩1.4T₩138.7B₩118.4B10.2%12.3%55.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Revenue on a DART-filed basis rose from KRW 1.05 trillion in 2022 to KRW 1.36 trillion in 2025, increasing for three consecutive years from 2023 through 2025. Operating profit rose from KRW 67.6 billion in 2022 to KRW 124.5 billion in 2023 (up 84.1%), then fell 20.6% to KRW 98.9 billion in 2024.

Operating profit in 2025 was KRW 138.7 billion, up 40.3%, the largest year of the 2022–2025 period, and the operating margin climbed from 7.7% in 2024 to 10.2% in 2025. Net profit attributable to controlling shareholders was smallest in 2024 at KRW 59.4 billion and rose 99.2% to KRW 118.4 billion in 2025.

Net profit including non-controlling interests, at KRW 117.7 billion in 2025, is a different figure and should be read separately. Factors behind the 2025 improvement include growth in the company's own businesses, higher equity-method income from affiliates' higher-margin operations, and lower one-off costs.

Operating cash flow, however, fell from KRW 83 billion in 2024 to KRW 47.7 billion in 2025, so cash generation did not move in step with the earnings recovery. The debt-to-equity ratio improved from 60.9% in 2024 to 55.2% in 2025, and total equity stood at KRW 959.2 billion at end-2025.

On a quarterly basis, third-quarter revenue rose from KRW 342.5 billion in 2025 to KRW 362.9 billion in 2026, up 5.9% year on year. Third-quarter operating profit, however, fell from KRW 39.3 billion to KRW 19.2 billion, reflecting a high base from a technology-export payment booked a year earlier at a subsidiary.

Operating profit reached KRW 59.1 billion in the second quarter of 2026, up 76.2% from the prior quarter, before falling 67.6% in the third quarter, so quarterly swings are large.

Net profit attributable to controlling shareholders over the last four quarters totaled KRW 134.2 billion, and the third quarter of 2026 at KRW 15.6 billion was down 51.8% year on year.

05

Industry analysis

Domestic pharmaceutical distribution operates on thin margins, so revenue growth does not translate into profit growth at the same pace. Hanmi Science is building its own businesses on top of this base, and the company says results spanned medical devices, cosmetics and consumer health.

In medical devices, overseas sales are at an early stage: first export revenue was recorded after the company's participation in MEDICA 2025. In dermocosmetics, the company entered the market with its ADESII brand.

From a group perspective, the performance of its core affiliate Hanmi Pharm, including product momentum and new-drug progress, feeds directly into holding-company earnings. iM Securities has argued that an IP-based platform role could increase patent-allocation income.

Press coverage describes the company as a model of a business-oriented holding company. Quarterly profit, however, is strongly affected by one-off items, such as a large new-drug technology-fee payment that was booked in the third quarter of 2025 at Hanmi Pharm. Short-term results therefore depend more on affiliate one-off items and group structure than on a sector cycle.

06

Outlook

The nearest checkpoint is MEDICA 2026 in Düsseldorf, Germany, from November 16 to 19, 2026, where the company is showing three hemostats and plans to strengthen existing partnerships and find new overseas partners.

Because overseas revenue only began in 2025, whether contracts from this show convert into export volume is the key item to track. On the affiliate side, the approval and launch timing of Hanmi Pharm's efpeglenatide matters, and the company reportedly targets approval and launch within 2026.

Patent-allocation income may also expand. The company is also widening distribution for its CAREMI and ADESII brands, including clinic channels for ADESII.

Cumulative third-quarter 2026 results, released as preliminary figures, were KRW 1.08 trillion in revenue, KRW 111.9 billion in operating profit and KRW 101.5 billion in net profit.

The next filing is the 2026 annual business report, due by the end of March 2027, and before that the fourth-quarter and full-year 2026 preliminary results are expected in early 2027.

Whether fourth-quarter operating profit moves beyond the third-quarter level of KRW 19.2 billion, and whether the full-year operating margin holds near 10%, are the items to check.

07

Valuation

PER
26.0×
PBR
3.3×
ROE
13.5%
EPS
₩1,981
BPS
₩15,636
Dividend per share
₩300

Set against recent earnings, the market capitalization equals several times the net profit attributable to controlling shareholders over the last four quarters, KRW 134.2 billion.

Compared with equity attributable to controlling shareholders of KRW 961.9 billion at end-2025, the market value sits in a range of substantial premium to book value.

Earnings recovered from KRW 59.4 billion in 2024 to KRW 118.4 billion in 2025, but quarterly profit fell sharply in the third quarter of 2026, so the trend over the last four quarters is mixed.

Because much of the profit comes from equity-method income and royalties, valuation interpretation is tied to affiliate performance and technology-export flows.

Operating cash flow of KRW 47.7 billion in 2025 was below net profit attributable to controlling shareholders of KRW 118.4 billion, so the gap between book profit and cash generation deserves attention. The dividend yield is in the low range at the current share price.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Expansion of own businesses

Healthcare revenue reached KRW 151.9 billion in 2025, up 19.6%, and the PRO-CALM cosmetics brand grew 75% to KRW 12.1 billion. Medical devices recorded first export revenue after the 2025 show, and CAREMI is widening pharmacy distribution. Own businesses are being added on top of a distribution-led revenue base.

Recovery in earnings capacity

Operating profit rose 40.3% to KRW 138.7 billion in 2025, lifting the operating margin to 10.2%. Net profit attributable to controlling shareholders rose 99.2% to KRW 118.4 billion, recovering from the 2024 low. The debt-to-equity ratio also declined from 60.9% to 55.2%, easing financial pressure.

Affiliate earnings and royalty flows

Hanmi Pharm reportedly targets approval and launch of efpeglenatide within 2026. iM Securities has said an IP-based platform role could increase patent-allocation income. The path from affiliate new drugs and technology exports to holding-company royalty and equity-method income remains open.

09

Bear factors

Volatility in quarterly profit

Third-quarter 2026 operating profit was KRW 19.2 billion, down 51.3% year on year and 67.6% from the second quarter's KRW 59.1 billion. A high base from a prior-year technology-export payment at a subsidiary contributed. Because quarterly profit depends on one-off items, continuity of the earnings trend is limited.

Low-margin distribution and external dependence

Most revenue comes from low-margin pharmaceutical distribution, and real profit relies heavily on equity-method income and royalties from affiliates. A slowdown at affiliates flows directly into holding-company earnings. High intra-group transaction volume means these arrangements can also shape reported results.

Governance and cash-flow weakness

During 2025, large off-market sales to fund inheritance tax reduced stakes held by key shareholders. Press coverage has also reported tension between the founding family and major shareholders. Operating cash flow fell from KRW 83 billion in 2024 to KRW 47.7 billion in 2025.

10

Risk factors

Governance risk

Tension between the founding family and major shareholders has been reported in the press. In 2025, off-market sales to fund inheritance tax significantly reduced stakes held by key family shareholders. Governance changes could affect strategic continuity and decision-making.

Affiliate and technology-export cycle

Holding-company profit has moved sharply by quarter in line with Hanmi Pharm's technology-fee payments and new-drug approval timing. Third-quarter 2026 operating profit fell partly from a high base in the prior year. If affiliate approvals or launches slip, equity-method and royalty income could also be delayed.

Cash generation and distribution structure

Operating cash flow was KRW 47.7 billion in 2025, down from KRW 83 billion in 2024. Because distribution revenue carries thin margins, top-line growth may not translate quickly into more cash. A widening gap between book profit and cash flow could weigh on financial flexibility.

11

What to watch next

  1. November 16–19, 2026

    Whether overseas discussions at MEDICA 2026 in Düsseldorf convert into export contracts for the three hemostats. Disclosed contract sizes would show the overseas revenue contribution of the medical device unit.

  2. End of December 2026

    Whether Hanmi Pharm's efpeglenatide meets its approval target within 2026. Approval and launch timing links to affiliate results and holding-company equity-method and royalty income.

  3. Early 2027

    Fourth-quarter and full-year 2026 preliminary results. Key items are whether fourth-quarter operating profit recovers from the third-quarter level of KRW 19.2 billion and whether the full-year operating margin holds near the 2025 level of 10.2%.

  4. End of March 2027

    Deadline for the 2026 annual business report. Confirmed full-year results, the debt-to-equity ratio and operating cash flow compared with KRW 47.7 billion in 2025 will be in this filing.

12

Overall view

Hanmi Science is a business-oriented holding company adding healthcare, cosmetics and medical-device businesses on top of a distribution-led revenue base.

Its 2025 DART-filed results show recovery, with operating profit of KRW 138.7 billion, an operating margin of 10.2% and net profit attributable to controlling shareholders of KRW 118.4 billion.

A large share of profit, however, comes from equity-method income and royalties, and third-quarter 2026 operating profit fell sharply on a high base from the prior year. Operating cash flow also declined in 2025, so book profit and cash generation did not move together.

Governance tensions and share transfers linked to inheritance tax remain medium-term variables. Strengths include expansion of own businesses and early overseas export results; weaknesses include quarterly volatility and dependence on affiliates.

The next checkpoints are export outcomes from MEDICA 2026 in November 2026, Hanmi Pharm's approval timing by year-end 2026, and fourth-quarter and full-year preliminary results in early 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. news.nate.com
  2. financialpost.co.kr
  3. m.comp.fnguide.com
  4. medicopharma.co.kr
  5. m.dailypharm.com
  6. hitnews.co.kr
  7. getnews.co.kr
  8. openbizdata.com
  9. comp.wisereport.co.kr
  10. newspost.kr
  11. thefairnews.co.kr
  12. pointdaily.co.kr
  13. pharmnews.com
  14. news.nate.com
  15. news1.kr
  16. datanews.co.kr
  17. ziksir.com
  18. supple.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis